Hudson Bay Capital Management’s Oaktree Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A ordinary share OACB.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-16,250
Closed -$11K 1480
2022
Q1
$11K Hold
16,250
﹤0.01% 1148
2021
Q4
$17K Buy
16,250
+5,000
+44% +$5.48K ﹤0.01% 1056
2021
Q3
$10K Hold
11,250
﹤0.01% 972
2021
Q2
$14K Hold
11,250
﹤0.01% 929
2021
Q1
$14K Hold
11,250
﹤0.01% 839
2020
Q4
$21K Buy
+11,250
New +$15.9K ﹤0.01% 576

Hudson Bay Capital Management's OACB.WS Position: Q2 2022 in Review

Hudson Bay Capital Management sold out of Oaktree Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A ordinary share (OACB.WS) in Q2 2022, closing a stake of 16,250 shares — an estimated $11K sold.

Hudson Bay Capital Management first reported a position in OACB.WS in Q4 2020 and held it in 6 quarters. The position peaked at $21K in Q4 2020. 0 funds tracked by Wall St. Rank hold OACB.WS as of Q2 2022.

  • Hudson Bay Capital Management reported no remaining Oaktree Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A ordinary share position as of Q2 2022 after selling out during the quarter.
  • Hudson Bay Capital Management sold 16,250 Oaktree Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A ordinary share shares in Q2 2022, an estimated $11K.
  • Hudson Bay Capital Management first reported a position in Oaktree Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A ordinary share in Q4 2020 and held it in 6 quarters.
  • Hudson Bay Capital Management's Oaktree Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A ordinary share position peaked at $21K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Oaktree Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A ordinary share as of Q2 2022.

Based on Hudson Bay Capital Management's 13F filing for Q2 2022, filed 12 Aug 2022.